ERBB2 and gastric cancer: Unlike Wang et al. [34] who described a significant association between lower PD-L1 expression and HER2 gene amplification in GC, we did not find any significant association between this molecular feature and pre-treatment NLR, TILs and PD-L1 expression, suggesting that this alteration did not have a predictive role in NAD-CT-treated LAGC.